Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...
Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
“Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS ...
At close: March 13 at 4:00:01 PM EDT Loading Chart for HALO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results